DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. 1996

N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, OH 45229, USA.

The immunogenicity and protective efficacy of a nucleic acid vaccine encoding the herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) gene under the control of the CMV immediate early gene promoter was examined. Mice immunized three times by intramuscular injection with the vaccine developed an HSV specific IgG but not IgA antibody response detectable in both serum and vaginal secretions. In addition, antigen-specific cellular immune responses were detected in splenic lymphocytes isolated from DNA immunized animals. Immunization reduced virus replication in the genital tract following a lethal intravaginal HSV-2 challenge. Furthermore, symptomatic genital HSV disease was reduced in immunized mice and the animals were completely protected from death. We conclude that a nucleic acid vaccine expressing HSV-1 gD induced both humoral and cell mediated immune responses in mice which proved highly protective against disease following virus challenge.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D005260 Female Females
D006558 Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. Genital Herpes,Herpes Simplex, Genital,Herpes Simplex Virus Genital Infection,Genital Herpes Simplex,Herpes, Genital
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014621 Vagina The genital canal in the female, extending from the UTERUS to the VULVA. (Stedman, 25th ed) Vaginas
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral

Related Publications

N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
August 1978, American journal of obstetrics and gynecology,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
December 1999, Vaccine,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
July 1990, The Journal of general virology,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
January 2010, Journal of pharmacological sciences,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
January 2008, Human vaccines,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
March 2000, Vaccine,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
January 2003, Viral immunology,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
January 2004, Virology,
N Bourne, and G N Milligan, and M R Schleiss, and D I Bernstein, and L R Stanberry
July 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Copied contents to your clipboard!